product launch

“In the third quarter, we continued to execute on our strategy with important pipeline advancements, significant approvals and successful new product launches.”

“We're securing our future by making important investments in our pipeline including through compelling, strategic business development like our completed acquisition of Verona Pharma and expanded U.S. manufacturing and R&D spending.”

“With each milestone we achieve, my conviction that we're well-positioned to drive the next chapter of success for our Company increases.”

If you're selling into pharma or hospital systems, KEYTRUDA subcutaneous approval (one-minute administration) is about to reshape infusion center economics — watch for procurement cycle changes in oncology clinics.